Growblox Life Sciences is seeking a patent for their marijuana-based products used to treat inflammatory diseases including Crohn’s disease and ulcerative colitis.
The Las Vegas-based company’s cannabinoid-containing complex mixtures (CCCM) work by disrupting the immune system’s pathway signals which contribute to IBD and other inflammatory diseases. The parent company, GB Sciences, claims their products are more effective than antihistamines and other medications traditionally used to fight inflammation and would cost less than the estimated $2 billion a year the U.S. currently spends on treatment for inflammatory diseases.
In addition to developing treatments for inflammatory diseases, the company is also working on a range of cannabis-based treatments for non-inflammatory diseases.
IBD News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.